BioMelbourne Network
Progressing BioIndustry

News and Opinions

Previous1 | 2 | 3 | 4

2015

July

Invion and Hovione Sign Joint Development and Licensing Agreement for Inhaled Zafirlukast

27 July 2015.  Australian drug development company Invion Limited (ASX: IVX)  has secured a commitment from Hovione Scientia Limited, an international pharmaceutical company expert in inhalation development and manufacturing, to progress development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.Invion and Hovione will collaborate to develop the proprietary novel techno... read more…

BioMelbourne Network - New Phone Number

We have a new phone number, please update your records and remove the old number.  BioMelbourne Network's new number is +61 (0)3 9667 8181 Nicole Pitcher Office Manager BioMelbourne Network Milton House, Level 2, 25 Flinders Lane Melbourne  Australia  3000 tel: +61 (0)3 9667 8181 mobile: +61 (0)409 182 900 email: npitcher@biomelbourne.org internet: www.biomelbourne.org   read more…

ARC Imaging Centre Work on Nanoparticles Published Today in Science

17 July 2015.  ARC Imaging Centre Work on Nanoparticles Published Today in Science. We are delighted to announce that our ARC Imaging Centre Associate Investigator Hans Elmlund's work on the structure of platinum nanoparticles has been published in Science today. Hans, a structural biologist at Monash University, worked with international colleagues including scientists at Berkeley, Princeton a... read more…

Gordagen Appoints Dr. Rocco Iannello as Director of Business Development

16 July 2015.  Gordagen Appoints Dr. Rocco Iannello as Director of Business Development. Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced the appointment of Dr. Rocco Iannello as Director of Business Development.Dr. Iannello will be responsible for Gordagen’s business development, including major international licensing a... read more…

MMV wins Tim Berners-Lee’s Open Data Innovation Award

14 July 2015.  Nominated by UK DFID, MMV chosen from a shortlist of 17 open data pioneers.MMV has won the Open Data Innovation Award, one of Five Open Data Awards presented by Tim Berners-Lee’s Open Data Institute (ODI) and hosted at Bloomberg London. The awards presented On Thursday, 9 July 2015, were in recognition of innovation and excellence in open data. MMV was one of 17 organizations sho... read more…

Global Biotech Industry Continues to Sizzle as Market Capitalization Surpasses US$1 Trillion

8 July 2015.  The global biotechnology industry reached new heights in 2014, setting records on virtually every major financial metric, including revenues, profitability and capital raised. These positive performance indicators, combined with several high-profile product successes and a strong year for new drug approvals, drove the industry’s total market capitalization above the US$1t threshol... read more…

BioMelbourne Network Announces Incoming Chair

8 July 2015.The BioMelbourne Network is pleased to announce that Mr Andrew Carter has been elected by the Board to succeed Mr Andrew Macdonald as Chair, effective from the 1st of July, 2015. Mr Andrew Macdonald has completed a distinguished period of service as Chair of the Network, following his appointment to the role in 2010. Andrew has provided strong leadership in overseeing the growth and... read more…

Nexvet and Zenoaq Enter Research and Development Collaboration

7 July 2015.  DUBLIN, Ireland, July 7, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the signing of a research and development agreement with leading Japanese animal health company Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.) to develop a number of therapeutic biologics for companion animals. The biologics will target undisclosed pro... read more…

Circadian Commences Wet AMD OPT-302 Clinical Trial

1 July 2015.  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) has commenced its Phase 1 study of OPT-302 in patients with wet age-related macular degeneration (wet AMD) following receipt of Institutional Review Board (IRB) approval and initiation of the five clinical trial sites in the US. The trial is under an investigational new drug (IND) authorisation received from the US Food and Dru... read more…
June

Invion Completes Dosing in Key Phase II Clinical Trial of Oral INV102 (NADOLOL) in Smoking Cessation

29 June 2015.  Invion Limited (ASX: IVX), an Australian drug development company, is pleased to announce that it   has completed dosing in INVSC001: “Efficacy and safety of beta-adrenoceptor inverse agonist, nadolol, in smoking cessation of patients with pre-existing COPD”.This double-blind, randomized, placebo-controlled Phase IIB clinical trial, is being performed in the United States under a... read more…